Log in with your email address username.

×

Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Comment] Radiotherapy for newly diagnosed oligometastatic prostate cancer

The standard of care for metastatic prostate cancer is systemic therapy in the form of androgen deprivation therapy with or without novel antiandrogens or chemotherapy.1 Administering local treatment to the primary tumour in the setting of metastatic prostate cancer has long been postulated to have a survival benefit on the basis of retrospective series.2–7 But such series can have selection bias in that patients undergoing local treatment can also have a low volume of metastatic disease (oligometastases), creating a major confounder in most analyses.

email